IPN60090

IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].

Product Specifications

CAS Number

[1853164-83-6]

UNSPSC

12352005

Target

Glutaminase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gls1-in-1.html

Purity

99.47

Solubility

DMSO : 31.43 mg/mL (ultrasonic)

Smiles

O=C(NC1=NN=C(CC[C@@H](F)CN2N=NC(C(NC)=O)=C2)C=C1)CC3=NC(C)=CC(OC4CC(F)(F)C4)=C3

Molecular Formula

C24H27F3N8O3

Molecular Weight

532.52

References & Citations

[1]Maria Emilia Di Francesco, et al. Gls1 inhibitors for treating disease. WO2016004404A2.|[2]Michael J Soth, et al. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 Nov 12;63 (21) :12957-12977.